# Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

> **NCT05228015** · PHASE1 · TERMINATED · sponsor: **Ikena Oncology** · enrollment: 67 (actual)

## Conditions studied

- Solid Tumors, Adult
- Solid Tumor
- Malignant Pleural Mesothelioma (MPM)
- Epithelioid Hemangioendothelioma (EHE)
- NF2 Deficient Mesothelioma
- Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes
- NF2 Deficiency
- YAP1 or TAZ Gene Fusions

## Interventions

- **DRUG:** IK-930
- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT05228015
- **Lead sponsor:** Ikena Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-07
- **Primary completion:** 2024-08-27
- **Final completion:** 2024-09-09
- **Target enrollment:** 67 (ACTUAL)
- **Why stopped:** Sponsor strategic reasons
- **Last updated:** 2024-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05228015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05228015, "Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05228015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*